Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS

Journal of the American Society of Nephrology : JASN14 Mar 2007Cited by 178 (Europe PMC)

PMID17360951DOI10.1681/asn.2006070778PepBankPUB-17360951

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 reduced urinary albumin excretion versus vehicle.
In plain wordsIn mice, exendin‑4 reduced urine albumin compared with vehicle.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary albumin excretion versus vehicle
Study
mousen: not reported in source
db/db mice
Comparator
Vehicle-treated db/db mice
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Urinary albumin excretion was significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4 compared with those in db/db mice that were treated with 0.5 nmol/kg exendin-4 and control db/db mice (P < 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095101
02AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, the higher exendin‑4 dose reduced urinary albumin excretion versus the lower dose.
In plain wordsIn mice, the higher exendin‑4 dose reduced urine albumin more than the lower dose.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary albumin excretion versus lower dose
Study
mousen: not reported in source
db/db mice
Comparator
0.5 nmol/kg exendin-4
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Urinary albumin excretion was significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4 compared with those in db/db mice that were treated with 0.5 nmol/kg exendin-4 and control db/db mice (P < 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095102
03AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 improved glucose tolerance versus other groups.
In plain wordsIn mice, exendin‑4 improved glucose tolerance compared with other groups.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose tolerance
Study
mousen: not reported in source
db/db mice
Comparator
Other groups
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Intraperitoneal glucose tolerance test was improved in db/db mice that were treated with 1 nmol/kg exendin-4 compared with other groups (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095103
04AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, fasting glucose did not differ significantly among exendin‑4 and control groups.
In plain wordsIn mice, fasting glucose did not differ significantly between exendin‑4 and control groups.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting blood glucose
Study
mousen: not reported in source
db/db mice
Comparator
Other db/db groups
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 wkAs given in this study (mouse).
Source sentences
Summary
Despite this, fasting blood glucose, glycated hemoglobin, and creatinine concentrations were not significantly different among db/db mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095104
05AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, glycated hemoglobin did not differ significantly among groups.
In plain wordsIn mice, glycated hemoglobin did not differ significantly between exendin‑4 and control groups.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlycated hemoglobin
Study
mousen: not reported in source
db/db mice
Comparator
Other db/db groups
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 wkAs given in this study (mouse).
Source sentences
Summary
Despite this, fasting blood glucose, glycated hemoglobin, and creatinine concentrations were not significantly different among db/db mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095105
06AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, creatinine did not differ significantly among groups.
In plain wordsIn mice, creatinine did not differ significantly between exendin‑4 and control groups.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCreatinine
Study
mousen: not reported in source
db/db mice
Comparator
Other db/db groups
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 8 wkAs given in this study (mouse).
Source sentences
Summary
Despite this, fasting blood glucose, glycated hemoglobin, and creatinine concentrations were not significantly different among db/db mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095106
07AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 reduced glomerular hypertrophy.
In plain wordsIn mice, exendin‑4 reduced enlargement of kidney filtering structures.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlomerular hypertrophy
Study
mousen: not reported in source
db/db mice
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Renal histology studies further demonstrated that glomerular hypertrophy, mesangial matrix expansion, TGF-beta1 expression, and type IV collagen accumulation and associated glomerular lipid accumulation were significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095107
08AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 reduced mesangial matrix expansion.
In plain wordsIn mice, exendin‑4 reduced expansion of tissue within kidney filters.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMesangial matrix expansion
Study
mousen: not reported in source
db/db mice
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Renal histology studies further demonstrated that glomerular hypertrophy, mesangial matrix expansion, TGF-beta1 expression, and type IV collagen accumulation and associated glomerular lipid accumulation were significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095108
09AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 reduced renal TGF-beta1 expression.
In plain wordsIn mice, exendin‑4 reduced kidney TGF-beta1 expression.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseRenal TGF-beta1 expression
Study
mousen: not reported in source
db/db mice
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Renal histology studies further demonstrated that glomerular hypertrophy, mesangial matrix expansion, TGF-beta1 expression, and type IV collagen accumulation and associated glomerular lipid accumulation were significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095109
10AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 reduced type IV collagen accumulation.
In plain wordsIn mice, exendin‑4 reduced collagen accumulation in kidney filters.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseType IV collagen accumulation
Study
mousen: not reported in source
db/db mice
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Renal histology studies further demonstrated that glomerular hypertrophy, mesangial matrix expansion, TGF-beta1 expression, and type IV collagen accumulation and associated glomerular lipid accumulation were significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095110
11AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 reduced glomerular lipid accumulation.
In plain wordsIn mice, exendin‑4 reduced fat accumulation in kidney filters.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlomerular lipid accumulation
Study
mousen: not reported in source
db/db mice
Outcome group
Lipids · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Renal histology studies further demonstrated that glomerular hypertrophy, mesangial matrix expansion, TGF-beta1 expression, and type IV collagen accumulation and associated glomerular lipid accumulation were significantly decreased in db/db mice that were treated with 1 nmol/kg exendin-4.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095111
12AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 reduced infiltrating glomerular inflammatory cells versus other groups.
In plain wordsIn mice, exendin‑4 reduced inflammatory cells in kidney filters compared with other groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlomerular inflammatory cells
Study
mousen: not reported in source
db/db mice
Comparator
Other groups
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Furthermore, there were fewer infiltrating inflammatory cells and apoptotic cells in the glomeruli of db/db mice that were treated with 1 nmol/kg exendin-4 compared with those in the other groups
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095112
13AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 reduced glomerular apoptotic cells versus other groups.
In plain wordsIn mice, exendin‑4 reduced dying cells in kidney filters compared with other groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlomerular apoptotic cells
Study
mousen: not reported in source
db/db mice
Comparator
Other groups
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
Furthermore, there were fewer infiltrating inflammatory cells and apoptotic cells in the glomeruli of db/db mice that were treated with 1 nmol/kg exendin-4 compared with those in the other groups
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095113
14AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 increased renal PPAR alpha immunoreactivity.
In plain wordsIn mice, exendin‑4 increased kidney PPAR alpha staining.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRenal PPAR alpha immunoreactivity
Study
mousen: not reported in source
db/db mice
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
accompanied by an increase in the renal immunoreactivity of peroxisome proliferator-activated receptor alpha and GLP-1 receptor-positive cells
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095114
15AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 increased renal GLP-1 receptor-positive cells.
In plain wordsIn mice, exendin‑4 increased kidney cells positive for GLP-1 receptors.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGLP-1 receptor-positive cells
Study
mousen: not reported in source
db/db mice
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
accompanied by an increase in the renal immunoreactivity of peroxisome proliferator-activated receptor alpha and GLP-1 receptor-positive cells
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095115
16AnimalAnimal study (in vivo)Mechanism
In db/db mice, exendin‑4 reduced urinary 8-hydroxy-deoxyguanosine.
In plain wordsIn mice, exendin‑4 reduced a urine marker of oxidative damage.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary 8-hydroxy-deoxyguanosine
Study
mousen: not reported in source
db/db mice
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
and a decrease in 24-h urinary 8-hydroxy-deoxyguanosine levels (P < 0.01, respectively) along with decreases in lipid content.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095116
17AnimalAnimal study (in vivo)Efficacy outcome
In db/db mice, exendin‑4 reduced lipid content.
In plain wordsIn mice, exendin‑4 reduced lipid content.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLipid content
Study
mousen: not reported in source
db/db mice
Outcome group
Lipids · Kidney and urinary
Studied dose
1 nmol/kg · 8 wkAs given in this study (mouse).
Source sentences
Summary
and a decrease in 24-h urinary 8-hydroxy-deoxyguanosine levels (P < 0.01, respectively) along with decreases in lipid content.
1 context sentence(design, population, supporting numbers)
Summary · context
Male db/db mice and db/m mice at 8 wk of age were treated with exendin-4 for 8 wk, whereas the control db/db mice received only vehicle.
Report a problemFND-1736095117

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02690883

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Nanfang Hospital, Southern Medical Universityn = 928 Apr 2016 to 30 Dec 2019

Diabetic Nephropathies

Trial page ClinicalTrials.govUpdated 9 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.